摘要
目的探讨血必净注射液对慢性阻塞性肺疾病急性加重期(AECOPD)合并呼吸衰竭患者的临床疗效。方法将58例AECOPD合并呼吸衰竭患者随机分为治疗组31例和对照组27例,对照组给予西医常规治疗,治疗组在此基础上加用血必净注射液50mL,2次/d,静脉滴注,疗程7d。观察2组血气分析、血清降钙素原(PCT)浓度变化及脱机成功率、脱机时间。结果治疗组血气、PCT改善情况明显优于对照组(P<0.01),脱机时间明显短于对照组(P<0.05),脱机成功率明显高于对照组(P<0.01)。结论在传统的西医疗法基础上加用血必净注射液可使AECOPD合并呼吸衰竭患者血清PCT水平快速显著下降,具有良好的治疗作用。PCT浓度与AECOPD的严重程度成正相关性,可以比较客观地评价其治疗效果和预后。
Objective To evaluate the clinical effect of Xuebijing Injection （XI） on the patients in acute exacerbation period of chronic obstructive pulmonary disease （AECOPD） with respiratory failure. Methods Fifty-eight patients in AECOPD with respiratory failure were randomly divided into the treatment （31 cases） and control （27 cases） groups. With the routine therapy in two groups, the patients in the treatment group were iv dripped with XI, twice daily for 7 d. Using blood gas analysis, the concentration change of serum procalcitonin （PCT）, the offline success ratio and offline time were observed. Results The blood gas analysis, the serum PCT level, the offline success ratio, and offline time were improved in the treatment group compared with those of the control group （P 0.05）. Conclusion XI combined with western medicine treatment has a good therapeutic effect on AECOPD.
出处
《药物评价研究》
CAS
2013年第3期206-209,共4页
Drug Evaluation Research
关键词
血必净注射液
慢性阻塞性肺疾病
呼吸衰竭
降钙素原
Xuebijing Injection
chronic obstructive pulmonary disease（COPD）
respiratory failure
procalcitonin（PCT）
